Skip to main content

Table 1 Patients and clinical outcomes with dasatinib monotherapy

From: Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation

No Age Sex Dasatinib dose BM relapse BCR-ABL mutation EFS, day Outcome / Event (cause of death)
1 56 M 100 mg QD No No 624* SCT in CMR
2 56 M 100 mg QD No No 149 dead (infection)
3 64 F 100 mg QD No No 318 CMR
4 68 M 100 mg QD Yes T315I 368 dead (PD)
5 67 F 100 mg QD Yes T315I 197 dead (PD)
6 22 F 100 mg QD No No 634* SCT in CMR
7 77 M 50 mg BID Yes T315I 221 dead (PD)
8 63 F 50 mg QD Yes T315I 106 dead (PD)
9 80 F 100 mg QD No No 269 CMR
10 32 M 100 mg QD No No 158 CMR
11 78 M 100 mg QD Yes No 114 dead (PD)
  1. BM, bone marrow; EFS, event-free survival; OS, overall survival; M, male; F, femal; QD, once a day; BID, twice a day; SCT, stem cell transplantation; CMR, complete molecular response; PD, progressive disease; * a date of SCT was evaluated as censoring for analysis of EFS.